MK-8931 (Verubecestat), a non-peptidic class of BACE1 inhibitor, which originally developed for AD treatment penetrates the blood-brain barrier (BBB) very well and blocks BACE1 activity efficiently in the brain [14, 15]. This evidence concerns the gene BACE1 and Alzheimer disease.